McMillan S. and Fox M., Failure of caffeine to influence induced mutation frequencies and the independence of cell killing and mutation induction in V79 Chinese hamster cells.
Mutation Res. 60 (1979) 91 - 107 [Abstract]

Suter W., Brennand J., McMillan S. and Fox M., Relative mutagenicity of antineoplastic drugs and other alkylating agents in V79 Chinese hamster cells; independence of cytotoxic and mutagenic responses.
Mutation Res. 73 (1980) 171 - 181 [Abstract]

McMillan S. and Fox M., Effects of metabolic inhibitors on cell lethality and mutation induction in Chinese hamster cells. I. Inhibitors of de novo purine synthesis and a comparison with the effects of caffeine.
Chem.-Biol. Interactions 36 (1981) 71 - 88 [Abstract]

Brennand J., McMillan S. and Fox M., Effects of metabolic inhibitors on cell lethality and mutation induction in Chinese hamster cells. II. The effect of post-treatment with non-toxic concentrations of thymidine.
Chem.-Biol. Interactions 36 (1981) 89 -106 [Abstract]

Friedberg E. C., Bonura T., Love J. D., McMillan S., Radany E. H. and Schultz R. A., The repair of DNA damage: Recent developments and new insights.
J. Supramolec. Struct. Cell. Biochem. 16 (1981) 91 - 103 [Abstract]

McMillan S., Edenberg H. J., Radany E. H., Friedberg R. C. and Friedberg E. C., The denV gene of bacteriophage T4 codes for both pyrimidine dimer-DNA glycosylase and apyrimidinic endonuclease activities.
J. Virol. 40 (1981) 211 - 223 [Abstract]

Bonura T., Radany E. H., McMillan S., Love J. D., Schultz R. A., Edenberg H. J. and
Friedberg E. C., Pyrimidine dimer-DNA glycosylases: Studies on bacteriophage T4 infected and on uninfected Escherichia coli.
Biochimie 64 (1982) 643 - 654 [Abstract]

Fox M., McMillan S., Durrant L. and Boyle J. M., Relative sensitivity of V79 and V79/79 cells to spontaneous and induced mutation to 6-thioguanine and ouabain resistance.
Mutation Res. 95 (1982) 339 - 352 [Abstract]

McMillan S., Seiden M. V., Houghten R. A., Clevinger B., Davie J. M. and Lerner R., Synthetic idiotypes: The third hypervariable region of murine anti-dextran antibodies.
Cell 35 (1983) 859 - 863 [Abstract]

Seiden M. V., Clevinger B., Srouji T., Davie J. M., McMillan S. and Lerner R., A synthetic peptide induces a new anti-dextran idiotype.
Ann. Immunol. 135C (1984) 77 - 82 [Abstract]

Seiden M. V., Clevinger B., McMillan S., Srouji A., Lerner R. and Davie J. M., Chemical synthesis of idiotopes: Evidence that antisera to the same JH1 peptide detect multiple binding site-associated idiotopes.
J. Exp. Med. 159 (1984) 1338 - 1350 [Abstract]

Seiden M. V., Heuckeroth R., Clevinger B., McMillan S., Lerner R. and Davie J. M., Hypervariable region peptides variably induce specific anti-idiotypic antibodies: An approach to determining antigenic dominance.
J. Immunol. 136 (1986) 582 - 587 [Abstract]

McMillan S., Literacy and Computer Literacy: Definitions and Comparisons.
Computers Educ. 27 (1996) 161 - 170 [Abstract]

Abstracts:

Fox M. and McMillan S., Lack of effect of caffeine post-treatment on UV and EMS induced mutation to purine analogue resistance in V79 Chinese hamster cells.
J. Supramolec. Struct. Supp. 2 (1978) 41.

McMillan S. L. H., Radany E. H. and Friedberg E. C., Evidence that pyrimidine dimer-DNA glycosylase and AP endonuclease activities are both coded by the denV gene of bacteriophage T4.
Fed. Proc. 40 (1981) 1763.

Seiden M. V., Clevinger B., Srouji T., Davie J. M., McMillan S. and Lerner R., A synthetic peptide induces a new anti-dextran idiotype.
Fed. Proc. 42 (1983) 705.

Seiden M. V., Heuckeroth R., Clevinger B., McMillan S., Lerner R. and Davie J. M., Experience with five synthetic peptides demonstrates variable ability to induce anti-idiotypic reagents.
Fed. Proc. 44 (1985) 1865.

Letters:

Manuscripts in preparation:

CD-ROM Products and Projects:

"Intravenous Antiarrhythmic Drugs:  Renaissance in Arrhythmia Management"

Cardinal Health Systems for Wyeth-Ayerst Laboratories, (Released May 1999).
Role:  Content repurposing, design and programming.
Status:  Final release.

"Insomnia:  Prevalence, Consequences & Costs"

iCardinal for Wyeth-Ayerst Laboratories, (Released December 2000).
Role:  Subject matter research and content development, initial CD-ROM program design.
Status:  Final release.

"Short Stature:  Human Growth & Development"

Department of Pediatrics, University of Minnesota, (Released November 2002).
Role:  Content adaptation and research, CD-ROM design and programming (PC & Mac), and project management.
Status:  Final release. [Support Site]

"A Patient's Guide to Moderate Hypertension"

School of Public Health, University of Minnesota.
Role:  Content development, interface design, CD-ROM programming, and project management.

"A Pharmacoeconomic Cost-Effectiveness Model for Breast and Colorectal Cancers"

Medicom Digital Inc. for a major international pharmaceutical company, (Released March 2003).
Role:  Content adaptation, algorithm development and validation, initial CD-ROM program design.
Status:  Final release. At least one, possibly two, publications are planned and a second, expanded version is in development.

"Atrial Fibrillation and Stroke"

Medicom Digital Inc. for a major international pharmaceutical company.
Role:  Content research, design and development, initial CD-ROM program design, pharmacoeconomic algorithm development and validation.
Status:  The first version of this program, a tutorial, is in final review. A pharmacoeconomic model has also been completed for inclusion in the second version, scheduled for release later this year.

"Sensitivity Analyses for Renal Transplant Parameters"

Medicom Digital Inc. for a major international pharmaceutical company, (Feasibility completed April 2002, program development pending).
Role:  Content research, data selection, sensitivity analyses and feasibility review.
Status:  This was a successful feasibility study to assess the utility of published data (US Renal Data System) for predictive modeling.

"An Interactive Pharmacoeconomic and Disease Progression Model for Type II Diabetes"

Medicom Digital Inc. for a major international pharmaceutical company.
Role:  Content research, algorithm and model development, and validation.
Status:  Algorithms and predictive model development completed for all major comorbidities. Content development finalized and CD-ROM programming commenced.